Back

Real-world single tertiary-care multidisciplinary experience with dabigatran, apixaban, rivaroxaban and warfarin in patients with renal failure and concomitant NVAF.

26 August 2017 (00:00 - 00:00)
Organised by:
Congress Presentation Part of: Poster session 4 - Stroke prevention Atrial fibrillation (AF) ESC Premium Access ESC Congress 2017

About the speaker

Photo
Doctor Francesco Melillo

IRCCS San Raffaele Scientific Institute, Milan (Italy)

53 More presentations in this session

Presentation thumbnail
Differences between randomized controlled clinical trials and real-world atrial fibrillation patients treated with oral anticoagulants - do we treat the same patients? Results from the CRAFT study
Doctor A. Tyminska (Warsaw, PL)
Abstract Slides
Presentation thumbnail
Which factors influence the choice of a non-vitamin K oral anticoagulant over warfarin for stroke prevention among atrial fibrillation patients? Insights from the prospective SPRINT-AF registry.
Doctor M. Gupta (Toronto, CA)
Abstract
Presentation thumbnail
Real-world effectiveness of stroke prevention in patients with non-valvular atrial fibrillation treated with rivaroxaban vs. phenprocoumon in germany - insights from the reload study
Professor H. Bonnemeier (Luebeck, DE)
Abstract Slides
Presentation thumbnail
Increased thromboprophylactic treatment of patients with atrial fibrillation after the introduction of NOACs - an analysis of sex and gender differences
Ms D. Loikas (Stockholm, SE)
Abstract Slides
Presentation thumbnail
Comparison of stroke- and bleed-related healthcare resource utilization (HCRU) among patients with non-valvular atrial fibrillation (NVAF), newly treated with oral anti-coagulants (OACs)
Doctor J. Franchino-Elder (Ridgefield, US)
Abstract

Access the full session

Session thumbnail
Poster session 4 - Stroke prevention

The Event

Event poster

ESC Congress 2017

26 August - 30 August 2017

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources